Mycobacterium fortuitum osteomyelitis in a peripheral blood stem cell transplant recipient.
Mycobacterium fortuitum is an uncommon, but well-recognized, pathogen in immunocompromised hosts, with special predilection for bone and soft tissue infections in solid organ transplant recipients. We describe a case of osteomyelitis due to this pathogen in a peripheral blood stem cell transplant recipient.
Tejan-Sie
S A
SA
Department of Internal Medicine, Cleveland Clinic Foundation, Ohio 44195, USA.
Avery
R K
RK
Mossad
S B
SB
D000284:Administration, Oral; D000328:Adult; D000583:Amikacin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D001706:Biopsy; D002440:Cefoxitin / Q000494:pharmacology / Q000627:therapeutic use; D002513:Cephamycins / Q000494:pharmacology / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D003646:Debridement; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008826:Microbial Sensitivity Tests; D009101:Multiple Myeloma / Q000628:therapy; D019907:Mycobacterium fortuitum / Q000187:drug effects / Q000302:isolation & purification*; D010019:Osteomyelitis / Q000382:microbiology* / Q000473:pathology / Q000628:therapy; D013977:Tibia / Q000473:pathology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002513:Cephamycins; D002939:Ciprofloxacin; D002440:Cefoxitin; D000583:Amikacin